4DX Shares 4DMedical Limited
ACCUMULATE ASX · ASXProprietary lung-imaging technology offers significant clinical adoption and commercialisation upside.
Future value: $4.37 (+20.96%) · 6-12 months · analyst consensus
Signal breakdown
- ▸Regulatory and hospital adoption milestones could materially accelerate revenue growth.
- ▾Below 50-day MA (-5.78%)
- ▸~21% upside to price target
Is 4DX a buy right now?
Trend: 4DX is trading below the 50-day average (-3.66%), RSI 61 — neutral momentum, with a 3-month return of +14.95%.
Valuation & quality: 4DMedical Limited trades on forward P/E -189.2, price-to-book 12.95; fundamentals show net margin 0.0%, return on equity -174.4%, revenue growth 42.3% year on year.
Analyst consensus: 3 analysts have a mean 12-month price target of A$4.37 (+21% vs the last close; range A$3.00 – A$6.00), consensus rating “none”.
Our screen: ACCUMULATE (score 1) — Proprietary lung-imaging technology offers significant clinical adoption and commercialisation upside.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| +48.80% | -32.60% | -1.00% | +14.10% | -19.90% | -5.80% | +24.30% | -13.20% |
Fundamentals
Analyst price target
Technical signals
About 4DMedical Limited
4DMedical Limited operates as a medical technology company in the United States and Australia. The company engages in medical research technology and development of a non invasive respiratory imaging solution.
Sector: Healthcare · Industry: Medical Devices · Australia · 181 employees · Website
Related Technology picks
Browse: all ASX stocks · Technology picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.